LivaNova Receives Hold Rating from Barclays, with a $58.00 Price Target.

LivaNova (LIVN) received a Hold rating from Barclays, with a price target of $58.00. Analyst Matt Miksic from Barclays has a 4-star rating and an average return of 5.6%. LivaNova also received a Hold from TR | OpenAI – 4o’s Lila Implantra, but a Buy rating from Goldman Sachs. The company's market cap is $2.92B with a P/E ratio of -13.72.

LivaNova (LIVN), a medical technology company specializing in neuromodulation, has recently faced a mixed bag of analyst ratings and a significant restructuring move. Analysts from Barclays and TR | OpenAI – 4o’s Lila Implantra have both given a Hold rating to the company, with a price target of $58.00 from Barclays. However, Goldman Sachs has a more optimistic view, giving LivaNova a Buy rating [1].

Barclays analyst Matt Miksic, who has a 4-star rating and an average return of 5.6%, cited concerns over the company's financial health and market conditions. Meanwhile, TR | OpenAI – 4o’s Lila Implantra echoed similar sentiments, while Goldman Sachs highlighted the company's potential for growth and innovation in the neuromodulation space.

LivaNova's market capitalization stands at $2.92 billion, with a P/E ratio of -13.72, indicating a highly undervalued stock. The company has been undergoing a significant restructuring aimed at improving its operational efficiency and extending its cash runway. This strategic move includes workforce reductions and cost-saving measures, similar to Fate Therapeutics' recent restructuring [2].

The company's lead product, the LivaNova Implant, continues to show promise, with ongoing clinical trials and regulatory approvals. However, the market conditions and competitive landscape in neuromodulation remain challenging.

As of the current date, July 2, 2025, LivaNova's stock price has been volatile, reflecting the diverging analyst views and the company's ongoing restructuring. Investors should closely monitor the company's financial performance and clinical trial results to gauge the potential impact on its stock price and market valuation.

References:
[1] https://www.panabee.com/news/livanova-receives-divergent-analyst-ratings-amid-restructuring
[2] https://www.ainvest.com/news/barclays-maintains-buy-rating-fate-therapeutics-2-00-price-target-2508/